---
title: "The Biotech Stock That's Too Risky for Most Investors"
description: "Recursion Pharmaceuticals (RXRX) aims to leverage AI in drug discovery, potentially positioning itself as a leading biotech stock. Analysts are optimistic, projecting a 53% price increase over the nex"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/259219188.md"
published_at: "2025-09-28T13:36:03.000Z"
---

# The Biotech Stock That's Too Risky for Most Investors

> Recursion Pharmaceuticals (RXRX) aims to leverage AI in drug discovery, potentially positioning itself as a leading biotech stock. Analysts are optimistic, projecting a 53% price increase over the next year, with no sell ratings among five analysts. However, the company, with a $2.1 billion market cap and no product sales yet, poses significant risks for investors. Its lead drug candidate, REC-617, is in early trials, with results expected in 2028. Given the high failure rate of biotech drugs, cautious investors may prefer to observe from a distance.

The artificial intelligence (AI) revolution has the potential to alter just about every business operation for the better. One area where investors are extra excited about productivity improvements is the drug development business.

The vast majority of experimental drugs that enter clinical trials never become marketable products, but by applying AI to the discovery process, **Recursion Pharmaceuticals** (RXRX 1.84%) plans to become a top-performing biotech stock.

Image source: Getty Images.

The handful of analysts following the stock seem to agree that AI-powered drug discovery could give the company an advantage. Among five analysts following the stock, none have a sell rating, and expectations are high. The average analyst following the company thinks the stock price can rise 53% from its closing price on Sep. 24, to $7.25 per share over the next 12 months.

So, investment bank analysts are convinced this is a good stock to buy, or at least worth holding. And the company sports a $2.1 billion market cap despite having no idea when it will start recording product sales. This indicates that everyday investors probably don't appreciate how much risk they're taking on with the shares.

Recursion's most advanced new drug candidate, REC-617, is in its first clinical trial. It's a novel CDK7 inhibitor that could become the first cancer treatment of its kind, if this study and subsequent trials succeed and approval is granted. Earlier this year, Recursion advanced REC-617 to the phase 2 portion of its ongoing study. Top-line results are expected in 2028.

Investors new to biotech need to remember that a majority of cancer drugs that pre-commercial companies advance from phase 1 to phase 2 clinical trials never earn approval or generate sales. Even if we assume AI-powered drug discovery allows Recursion to pick winners twice as often as its peers, there's still a very strong chance that its lead candidate will fail to generate any sales. For most investors, it's best to watch this stock's story play out from a safe distance.

### Related Stocks

- [RXRX.US - Recursion Pharmaceuticals](https://longbridge.com/en/quote/RXRX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Got $200? 1 artificial intelligence (AI) stock to buy and hold for the long term | Why this AI leader probably won't tumble from its mountain top any time soon. | [Link](https://longbridge.com/en/news/275702754.md) |
| Should You Bet on a Short Squeeze in SoundHound AI Stock Now? | Should You Bet on a Short Squeeze in SoundHound AI Stock Now? | [Link](https://longbridge.com/en/news/275918992.md) |
| Forget AI stocks: This pharma giant is using AI to dominate drug discovery | And there's more than one way to monetize this technology. | [Link](https://longbridge.com/en/news/276017486.md) |
| 1 artificial intelligence (AI) stock investors are buying on the dip | This key AI stock got hit hard, and smart investors saw a big opportunity. | [Link](https://longbridge.com/en/news/275996696.md) |
| Shield AI Looking to Raise Up to $1 Billion in New Funding Round | Shield AI Looking to Raise Up to $1 Billion in New Funding Round | [Link](https://longbridge.com/en/news/275921852.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.